Endothelial Dysfunction in Systemic Lupus Erythermatosus

被引:0
|
作者
Badawi, Aysha I. Z. [1 ]
Abd Al Salam, Randa F. [1 ]
El Wahab, Amal A. [2 ]
机构
[1] Cairo Univ, Dept Internal Med, Fac Med, Cairo, Egypt
[2] Cairo Univ, Dept Clin & Chem Pathol, Cairo, Egypt
关键词
atherosclerosis-endothelium-systemic lupus erythermatosus;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Despite improved prognosis, patients with systemic Lupus, remain at increased risk of early vascular events due to premature atherosclerosis. We assessed the endothelial dysfunction in SLE as a marker of early atherosclerosis. In thirty seven (37) female patient endothelial dependant vasodilatation (EDD) was assessed at the brachial artery in response to shear stress and glyceril trinitrate administration (NMD), intimae media thickness of the common carotid artery was also measured using high resolution B-Mode ultrasonography., anticardolipin antibodies (done only in 18 patients) Lipid profiles, ANA were also assessed. No statistically significant difference between patients and control in basal FMD (D-1) (P=0.5) or percent change in flow mediated dilation (D-2) P = 0.3 and no change in NMD (P = 0.2). There was weak but statistically significant correlation between FMD% and NMD% (r = 0.3, P = 0.05). Despite the disease activity according to SLEDAI (where 45.9% of patients were severely active) there was no correlation between either disease activity and FMD (r =0.03, P = 0.8), or disease duration (2.4 +/- 3.3 years) (r = 0.7, P = 0.8) Weak but statistically significant negative correlation between hypercholesterolemia and endothelial dysfunction (r = 0.3, P = 0.05). We tried to find differences between patients themselves dividing them into those with FMD <10% (n = 23 patient, 62.2%) FMD >= 10% (n = 14 patient, 37.8%) or FMD %/ NMD % < 0.7 (n = 23 patient, 62%), FMD % /NMD> 0.7 (n = 14 patient, 38%). However no significant differences between them as regard clinical and laboratory data. In conclusion, FMD was not different between patients and control thus its use as a predictor of future cardiovascular events is questionable. [Aysha I.Z. Badawi, Randa F Abd Al Salam, Amal A El Wahab. Endothelial Dysfunction In Systemic Lupus Erythermatosus. Life Science Journal 2010;7(4):98-104]. (ISSN: 1097-8135).
引用
收藏
页码:98 / 104
页数:7
相关论文
共 50 条
  • [21] Caffeine improves systemic lupus erythematosus endothelial dysfunction by promoting endothelial progenitor cells survival
    Orefice, Valeria
    Ceccarelli, Fulvia
    Barbati, Cristiana
    Buoncuore, Giorgia
    Pirone, Carmelo
    Alessandri, Cristiano
    Conti, Fabrizio
    RHEUMATOLOGY, 2024,
  • [22] Endothelial Dysfunction in Systemic Lupus Erythematosus and Systemic Sclerosis: A Common Trigger for Different Microvascular Diseases
    Moschetti, Liala
    Piantoni, Silvia
    Vizzardi, Enrico
    Sciatti, Edoardo
    Riccardi, Mauro
    Franceschini, Franco
    Cavazzana, Ilaria
    FRONTIERS IN MEDICINE, 2022, 9
  • [23] Association between inflammatory markers and endothelial dysfunction in patients with systemic lupus erythematosus
    Shevchuk, S. V.
    RHEUMATOLOGY, 2007, 46 : I79 - I79
  • [24] INDICATIONS OF VASCULAR ENDOTHELIAL-CELL DYSFUNCTION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    BYRON, MA
    ALLINGTON, MJ
    CHAPEL, HM
    MOWAT, AG
    CEDERHOLMWILLIAMS, SA
    ANNALS OF THE RHEUMATIC DISEASES, 1987, 46 (10) : 741 - 745
  • [25] Effect of ezetimibe plus pravastatin on endothelial dysfunction in patients with systemic lupus erythematosus
    Vera-Lastra, O.
    Mendez-Flores, S.
    Cruz-Dominguez, M. P.
    Medina, G.
    Calderon-Aranda, E.
    Jara, L. J.
    LUPUS, 2016, 25 (07) : 741 - 748
  • [26] Non-invasive detection of endothelial dysfunction in patients with systemic lupus erythematosus
    Kiss, E.
    Soltesz, R.
    Der, H.
    Kocsis, Z.
    Tarr, T.
    Paragh, G.
    Szegedi, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 201 - 201
  • [27] Systemic lupus erythematosus (SLE) is an independent risk factor for endothelial dysfunction.
    El-Magadmi, M
    Bodill, H
    Ahmad, Y
    Bernstein, RM
    Walker, MG
    Bruce, IN
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S373 - S373
  • [28] Endothelial Dysfunction, clinical corelation and atorvastatin therapy in patients with systemic lupus erythematosus
    Felea, I.
    Rednic, N.
    Damian, C.
    Nicoara, I.
    Poanta, L.
    Pentilescua, D.
    Leucuta, D.
    Bolosiu, H. D.
    Rednic, S.
    JOINT BONE SPINE, 2008, 75 (02) : 247 - 247
  • [29] Upregulated vasoactive lipid mediators in systemic lupus erythematosus contribute to endothelial dysfunction
    Munoz, Maria Dolores Camacho
    Saxton, Sophie N.
    Heagerty, Anthony M.
    Nicolaou, Anna
    JOURNAL OF VASCULAR RESEARCH, 2023, 60 (SUPP1) : 52 - 52
  • [30] ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS WITHOUT PREVIOUS CARDIOVASCULAR EVENTS
    Taraborelli, M.
    Sciatti, E.
    Bonadei, I.
    Terlizzi, V.
    Fredi, M.
    Zani, R.
    Cancarini, G.
    Tincani, A.
    Franceschini, F.
    Vizzardi, E.
    Cavazzana, I.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S102 - S102